INTRAPERITONEAL YTTRIUM-90-LABELED MONOCLONAL-ANTIBODY IN OVARIAN-CANCER

被引:132
|
作者
STEWART, JSW
HIRD, V
SNOOK, D
DHOKIA, B
SIVOLAPENKO, G
HOOKER, G
PAPADIMITRIOU, JT
ROWLINSON, G
SULLIVAN, M
LAMBERT, HE
COULTER, C
MASON, WP
SOUTTER, WP
EPENETOS, AA
机构
[1] HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,IMPERIAL CANC RES FUND,DEPT CLIN ONCOL,ONCOL GRP,LONDON W11 0HS,ENGLAND
[2] ST MARYS HOSP,DEPT GYNAECOL,LONDON,ENGLAND
[3] ST MARYS HOSP,DEPT ONCOL,LONDON,ENGLAND
[4] HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT GYNAECOL,LONDON W12 0HS,ENGLAND
[5] HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT IMMUNOL,LONDON W12 0HS,ENGLAND
关键词
D O I
10.1200/JCO.1990.8.12.1941
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
From March 1987 to March 1988, a phase I to II study was carried out in 25 patients with ovarian cancer. They received escalating doses of intraperitoneally (IP) administered yttrium-90 (Y-90)-labeled monoclonal antibody, HMFG1, against a tumor cell-surface antigen. Myelosuppression prevented an escalation of the administered Y-90 activity above 25 mCi. Y-90-labeled antibody was absorbed from the peritoneal cavity into the circulation. Maximum blood Y-90 activity was observed 40 hours after the IP injection with a mean of 21% of the injected activity (range, 14.2% to 26.4%) in the circulation. The radiation dose the bone marrow received from circulating Y-90-labeled antibody (the blood radiation dose) was calculated by applying the Medical Internal Radiation Dose (MIRD) formulation to the measured Y-90 activity in patients blood. Myelosuppression occurred following calculated blood radiation doses to bone marrow of only 10 to 30 cGy. The excessive myelosuppression following such modest radiation doses from circulating Y-90-labeled antibody could be explained by the uptake of Y-90 by bone. In an attempt to reduce bone absorption of Y-90, seven patients received an intravenous (IV) infusion of EDTA (Sinclair Pharmaceuticals Ltd, Godalming, United Kingdom). This increased the urinary excretion of Y-90 from a mean of 11.1% to 32.3% of the injected activity (P = .0001). Fourteen patients had assessable tumor at laparoscopy. Tumor regression was observed in one patient, and palliation of ascites in a further patient.
引用
收藏
页码:1941 / 1950
页数:10
相关论文
共 50 条
  • [31] EFFECT OF YTTRIUM-90-LABELED ANTI-CARCINOEMBRYONIC ANTIGEN MONOCLONAL-ANTIBODY ON THE MORPHOLOGY AND PHENOTYPE OF HUMAN-TUMORS GROWN AS PERITONEAL CARCINOMATOSIS IN ATHYMIC MICE
    ESTEBAN, JM
    HYAMS, DM
    BEATTY, BG
    WANEK, P
    BEATTY, JD
    CANCER, 1989, 63 (07) : 1343 - 1352
  • [32] USE OF YTTRIUM-90-LABELED ANTI-TAC ANTIBODY IN PRIMATE XENOGRAFT TRANSPLANTATION
    COOPER, MM
    ROBBINS, RC
    GOLDMAN, CK
    MIRZADEH, S
    BRECHBIEL, MW
    STONE, CD
    GANSOW, OA
    CLARK, RE
    WALDMANN, TA
    TRANSPLANTATION, 1990, 50 (05) : 760 - 765
  • [33] Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival
    Oei, Angele L.
    Verheijen, Rene H.
    Seiden, Michael V.
    Benigno, Benedict B.
    Lopes, Alberto
    Soper, John T.
    Epenetos, Agamemnon A.
    Massuger, Leon F.
    INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (12) : 2710 - 2714
  • [34] PSEUDOMONAS EXOTOXIN COUPLED TO A MONOCLONAL-ANTIBODY AGAINST OVARIAN-CANCER INHIBITS THE GROWTH OF HUMAN OVARIAN-CANCER CELLS IN A MOUSE MODEL
    WILLINGHAM, MC
    FITZGERALD, DJ
    PASTAN, I
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (08) : 2474 - 2478
  • [35] Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate model
    Nemecek, ER
    Hamlin, DK
    Fisher, DR
    Krohn, KA
    Pagel, JM
    Appelbaum, FR
    Press, OW
    Matthews, DC
    CLINICAL CANCER RESEARCH, 2005, 11 (02) : 787 - 794
  • [36] HUMAN MONOCLONAL-ANTIBODY DEVELOPED AGAINST OVARIAN-CANCER CELL-SURFACE ANTIGEN
    CHAUDHURI, TR
    ZINN, KR
    MORRIS, JS
    MCDONALD, GA
    LLORENS, AS
    CHAUDHURI, TK
    CANCER, 1994, 73 (03) : 1098 - 1104
  • [37] ACTIVATION OF CELLULAR-IMMUNITY AFTER INTRACAVITARY MONOCLONAL-ANTIBODY THERAPY OF OVARIAN-CANCER
    KOSMAS, C
    EPENETOS, AA
    COURTENAYLUCK, NS
    CANCER, 1994, 73 (12) : 3000 - 3010
  • [38] IMMUNOSCINTIGRAPHY OF OVARIAN-CANCER WITH INDIUM-111-LABELED OV-TL 3 F(AB')2 MONOCLONAL-ANTIBODY
    MASSUGER, LFAG
    KENEMANS, P
    CLAESSENS, RAMJ
    VERHEIJEN, RHM
    SCHIJF, CPT
    STRIJK, SP
    POELS, LG
    VANHOESEL, RGCM
    CORSTENS, FHM
    JOURNAL OF NUCLEAR MEDICINE, 1990, 31 (11) : 1802 - 1810
  • [39] A MONOCLONAL-ANTIBODY RADIOIMMUNOASSAY FOR AN ANTIGENIC DETERMINANT CA125 IN OVARIAN-CANCER PATIENTS
    LIAN, LJ
    HU, XF
    LIU, WS
    WU, AJ
    CHINESE MEDICAL JOURNAL, 1986, 99 (09) : 721 - 726
  • [40] IMMUNOHISTOLOGY OF NORMAL AND OVARIAN-CANCER TISSUE WITH A MONOCLONAL-ANTIBODY TO PLACENTAL ALKALINE-PHOSPHATASE
    SUNDERLAND, CA
    DAVIES, JO
    STIRRAT, GM
    CANCER RESEARCH, 1984, 44 (10) : 4496 - 4502